Global pharmaceutical supply chains enable opioid proliferation in West Africa: systemic underregulation and corporate accountability gaps
Original framing: “Indian pharma fuels Africa’s ‘zombie drug’ and opioid crisis” — The Japan Times
The opioid crisis in West Africa mirrors historical patterns of drug trafficking enabled by colonial trade routes and post-colonial economic policies. During the 1980s-90s, deregulation in the US pharmaceutical industry preceded the opioid epidemic, suggesting a global pattern of corporate profit-driven deregulation. Colonial-era cash crop economies disrupted local subsistence systems, creating conditions for later substance abuse crises.
The West African opioid crisis is a symptom of a globalized pharmaceutical supply chain that prioritizes profit over public health, enabled by weak international regulation and corporate impunity.
Historical patterns reveal how deregulation and colonial legacies create conditions for substance abuse crises, while indigenous knowledge systems offer culturally grounded alternatives that are systematically marginalized. The crisis demands a systemic response: binding international treaties to regulate precursor chemicals, integration of indigenous healing practices into harm reduction, and economic diversification to address root causes. Without these measures, the proliferation of synthetic opioids will continue, mirroring the US opioid epidemic and exacerbating social fragmentation. The solution lies in dismantling the structures that enable corporate harm while centering the voices and wisdom of affected communities.